AVTX vs. RDHL, PIRS, MNPR, KPRX, PPBT, HUGE, EDSA, IMNN, ELAB, and AKTX
Should you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include RedHill Biopharma (RDHL), Pieris Pharmaceuticals (PIRS), Monopar Therapeutics (MNPR), Kiora Pharmaceuticals (KPRX), Purple Biotech (PPBT), FSD Pharma (HUGE), Edesa Biotech (EDSA), Imunon (IMNN), Elevai Labs (ELAB), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical preparations" industry.
Avalo Therapeutics (NASDAQ:AVTX) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk.
RedHill Biopharma received 422 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 68.98% of users gave RedHill Biopharma an outperform vote while only 31.25% of users gave Avalo Therapeutics an outperform vote.
RedHill Biopharma has higher revenue and earnings than Avalo Therapeutics.
In the previous week, RedHill Biopharma had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for RedHill Biopharma and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.59 beat RedHill Biopharma's score of 0.47 indicating that Avalo Therapeutics is being referred to more favorably in the media.
87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 7.2% of RedHill Biopharma shares are held by institutional investors. 0.2% of Avalo Therapeutics shares are held by insiders. Comparatively, 6.8% of RedHill Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Avalo Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 3.47, suggesting that its share price is 247% more volatile than the S&P 500.
RedHill Biopharma has a net margin of 0.00% compared to Avalo Therapeutics' net margin of -1,639.50%. RedHill Biopharma's return on equity of 0.00% beat Avalo Therapeutics' return on equity.
Summary
RedHill Biopharma beats Avalo Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Avalo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalo Therapeutics Competitors List
Related Companies and Tools
